Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
PLTR$172.22-6.14(-3.44%)Election Day Trading Splits the Benchmarks, With the Dow Lower and the Nasdaq Higher11:31:59 AM ETETOLF$1.230.00(0.00%)Enterprise Products Covers Its Distribution 1.9 Times. Here Are 3 More High-Yield Stocks11:17:28 AM ETPFE$30.50-0.20(-0.65%)PFE Beats Q3 Earnings & Sales Estimates, Raises 2026 Guidance11:16:08 AM ETSHOP$145.12-11.08(-7.09%)Shopify president Harley Finkelstein: Shopping through AI channels is 'growing quite quickly'11:09:07 AM ETPLTR$172.22-6.14(-3.44%)U.S. Companies Now Pay Palantir More Than the U.S. Government for the First Time11:07:13 AM ETPLTR$172.22-6.14(-3.44%)Palantir's CEO on Q3 results and boom in company's commercial business11:06:12 AM ETJPM$336.45-4.19(-1.23%)JPM Opens Dubai Private Banking Branch: Will Wealth Revenues Grow?11:06:05 AM ETNVDA$207.70+5.50(+2.72%)Nvidia up over 3%: what's driving Tuesday's rally?11:05:30 AM ETABBV$288.86-0.02(-0.01%)AbbVie Hit a New High After Earnings. There's More Upside Left.11:03:57 AM ETAAPL$331.56-7.03(-2.08%)AAPL Q4 Earnings Call Highlights Supply Risks and AI Investment11:01:45 AM ETSPCX$140.43+4.09(+3.00%)SpaceX Q3 Earnings Call Highlights Aggressive AI Compute Expansion11:01:21 AM ETPLTR$172.22-6.14(-3.44%)"Phenomenal" PLTR Earnings Meet Tech Slowdown: Stock Faces AI & Technical Headwinds11:00:05 AM ETSPCX$140.43+4.09(+3.00%)Why Anthropic's IPO May Have Just Gotten a Whole Lot Riskier11:00:02 AM ETSPCX$140.43+4.09(+3.00%)SpaceX Just Delivered a Monster Quarter, but the Stock Is Still Down 38% From Its High. The Reasons Are Obvious.11:00:00 AM ETTSM$405.05+6.61(+1.66%)Taiwan Semi or Broadcom: If I Could Only Own 1 for the Next 5 Years, It Would Be This11:00:00 AM ETCRWD$245.69+3.91(+1.62%)CrowdStrike Is Preparing for an AI Threat That Could Already Be Inside the Company10:55:03 AM ETTSLA$398.28-5.58(-1.38%)QUICK SPARK: Elon Musk Says 'Vote Red' — SpaceX And Tesla Have Much To Gain10:53:51 AM ETPFE$30.50-0.20(-0.65%)UPDATE 4-Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results10:52:11 AM ETDIS$113.17+0.03(+0.03%)Disney's Cost-Cutting Push Could Put Its Stock Rally to the Test10:51:00 AM ETAAPL$331.56-7.03(-2.08%)Apple shares fall despite profit growth as traders fear rising chip costs10:49:02 AM ETCRM$222.31-3.79(-1.68%)The Selloff Didn't Stop Salesforce From Spending $2.7 Billion on an AI Startup10:48:10 AM ETETOLF$1.230.00(0.00%)Super Micro Climbs 4% Ahead of Earnings as AI Server Stocks Bounce; Hewlett Packard Enterprise Rallies 6%, Dell Gains 5%10:47:51 AM ETCOP$144.27-2.58(-1.76%)Why ConocoPhillips (COP) is a Top Growth Stock for the Long-Term10:46:33 AM ETTSM$405.05+6.61(+1.66%)Until Next Gen Computing Implodes I'll Keep Buying Taiwan Semiconductor10:45:30 AM ET

ARVN · NASDAQ

Arvinas, Inc.

$6.89 -0.65 (-8.62%)

Company overview

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766, an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$445M
Employees
430
Headquarters
New Haven, CT
Website
arvinas.com
CEO
Randy Teel
Listed
September 27, 2018
P/E
-2.10
Dividend yield
0.00%

Company financials

Revenue
$89.4M
Gross profit
$87.1M
Operating income
-$250M
EBITDA
-$232M
Net income
-$221M
EPS
-$3.26
Total assets
$648M
Total debt
$8.6M
Gross margin
97.43%
Net margin
-247.54%
Earnings yield
-47.59%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

6.557.819.0710.3311.59
ARVN 1D NASDAQ O7.81H7.83L7.37C7.54-0.33 (-4.13%)Vol677.17K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
ARVNArvinas, Inc. Stock news What Arvinas (ARVN) Said on Its Q3 Earnings Call MarketBeat
ARVNArvinas, Inc. Stock news Arvinas, Inc. (ARVN) Reports Q3 Loss, Misses Revenue Estimates Zacks Investment Research
ARVNArvinas, Inc. Stock news Arvinas Q3 revenue drops sharply on lower milestone payments Reuters
ARVNArvinas, Inc. Stock news BRIEF-Arvinas Q3 Revenue USD 500 Thousand Reuters
ARVNArvinas, Inc. Press release Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire
ARVNArvinas, Inc. Press release Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation GlobeNewswire
ARVNArvinas, Inc. Press release Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026 GlobeNewswire
ARVNArvinas, Inc. Stock news Reasons Why Investors Should Consider Betting on Arvinas Stock Zacks Investment Research
ARVNArvinas, Inc. Press release Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson's Disease GlobeNewswire
ARVNArvinas, Inc. Press release Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson's Disease and Movement Disorders® GlobeNewswire
ARVNArvinas, Inc. Press release Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology Candidate GlobeNewswire
ARVNArvinas, Inc. Stock news Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
ARVNArvinas, Inc. Press release Arvinas to Participate in Upcoming Investor Conferences GlobeNewswire
ARVNArvinas, Inc. Press release Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
ARVNArvinas, Inc. Stock news Connor Clark & Lunn Investment Management Ltd. Invests $1.39 Million in Arvinas, Inc. $ARVN Defense World
ARVNArvinas, Inc. Stock news Arvinas: Veppanu Approval Underlines Degrader Platform Promise - I'm Bullish Seeking Alpha
ARVNArvinas, Inc. Stock news Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know Zacks Investment Research
ARVNArvinas, Inc. Stock news Arvinas Q2 Earnings Call Highlights Defense World
ARVNArvinas, Inc. Stock news Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript Seeking Alpha
ARVNArvinas, Inc. Stock news Arvinas Q2 Earnings Call Highlights MarketBeat
See more
FAQ

Questions about Arvinas, Inc.

What does Arvinas, Inc. do?
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766, an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc.
What is ARVN's market cap?
Arvinas, Inc. (ARVN) is a listed stock with a live quote. The latest market cap on this page is $445M.
Where is Arvinas, Inc. headquartered?
Arvinas, Inc. is headquartered in New Haven, CT.
How do I get ARVN news from the API?
Call GET /v1/news?tickers=ARVN. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does ARVN news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for ARVN, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the ARVN price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs